Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy-Reference-Cited by-同舟云学术

Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy

Published:2010-08 Issue:2 Volume:76 Page:430-434
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Vickers Michael M.,Choueiri Toni K.,Rogers Miranda,Percy Andrew,Finch Daygen,Zama Ivan,Cheng Tina,North Scott,Knox Jennifer J.,Kollmannsberger Christian,McDermott David F.,Rini Brian I.,Heng Daniel Y.

Publisher

Elsevier BV

Subject

Urology

Reference19 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

2. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial;Escudier;Lancet,2007

3. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206;Rini;J Clin Oncol,2008

4. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med,2007

5. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of the response to antiangiogenic sunitinib therapy by non-invasive hybrid diffuse optics in renal cell carcinoma;Biomedical Optics Express;2024-09-06

2. Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma;Cancers;2019-07-17

3. Real-world evidence in metastatic renal cell carcinoma;Tumori Journal;2018-03

4. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy;American Journal of Roentgenology;2017-12

5. Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma;Translational Oncology;2017-06